To assess the impact of screening programmes in reducing the prevalence of 2 Chlamydia trachomatis, mathematical and computational models are used as a 3 guideline for decision support. Unfortunately, large uncertainties exist about the 4 parameters that determine the transmission dynamics of C. trachomatis. Here, we 5 use a SEIRS (susceptible-exposed-infected-recovered-susceptible) model to criti-6 cally analyze the turnover of C. trachomatis in a population and the impact of a 7 screening programme. We perform a sensitivity analysis on the most important 8 steps during an infection with C. trachomatis. Varying the fraction of the infections 9 becoming symptomatic as well as the duration of the symptomatic period within 10 the range of previously used parameter estimates has little effect on the transmis-11 sion dynamics. However, uncertainties in the duration of temporary immunity and 12 the asymptomatic period can result in large differences in the predicted impact of 13 a screening programme. We therefore analyze previously published data on the 14 persistence of asymptomatic C. trachomatis infection in women and estimate the 15 mean duration of the asymptomatic period to be longer than anticipated so far, 16 namely 433 days (95% CI: 420-447 days). Our study shows that a longer duration 17 of the asymptomatic period results in a more pronounced impact of a screening 18 programme. However, due to the slower turnover of the infection, a substantial 19 reduction in prevalence can only be achieved after screening for several years or 20 decades. 21 23 ted disease in many developed countries (World Health Organization, 2001). In women, 24 infection can lead to pelvic inflammatory disease (PID) which can result in chronic 25 pelvic pain, ectopic pregnancy or infertility (Cates and Wasserheit, 1991). Whilst acute 26 infection can cause urethral discharge and pain on urination in men and symptoms such 27 as vaginal discharge in women, most infections are asymptomatic and therefore remain 28 undiagnosed. Screening and treatment of young adult women (Centers for Disease Con-29 trol and Prevention, 2006) or women and men (Department of Health, 2004) is widely 30 promoted as an intervention to reduce the duration of infection and thus lower the 31 prevalence of C. trachomatis and reduce the incidence of possible sequelae.
Introduction
Infection with Chlamydia trachomatis is the most common bacterial sexually transmit-equations: dS dt = −β(I a + I s )S + cI a + (r s + c)I s + µR,
dR dt = r a I a − µR.
There is a wide range of published estimates for the duration of the incubation 102 time, 1/γ, the fraction of infections becoming asymptomatic, f , and the duration of the 103 asymptomatic and symptomatic period, 1/r a and 1/r s , respectively (Table 1) . Based 104 on observations from studies in mice, it has been suggested that natural clearance may 105 be followed by temporary immunity of length 1/µ (Brunham and Rey-Ladino, 2005) . 106 The parameter c denotes the effect of screening the population where asymptomatically 107 or symptomatically infected people are diagnosed and treated so that they immediately 108 become susceptible again. The rate at which susceptible people have contact with inp = γµ(β − a − b) β(γµ + aγ + aµ + bµ) ,
a = f r a (r s + c) f r s + (1 − f )r a + c and b = (r a + c)(1 − f )r s f r s + (1 − f )r a + c + c.
The expression for the prevalence p as a function of a and b can be explained by a 121 simpler SEIRS model that does not distinguish between symptomatic and asymptomatic 122 states. In such a model, a denotes the rate at which infected people recover and develop 123 temporary immunity and b the rate at which infected people become directly susceptible 124 again. The steady-state prevalence, p, of this simpler model is directly given by Eq. (6).
125
The necessary 'infection rate' β to obtain a given prevalence p is:
By choosing a and b as in Eq. (7), we can distinguish between symptomatically and 127 asymptomatically infected individuals as described in the full model from Eq. (1) -(5).
128
For any given combination of disease-specific parameters, we wish to calculate the 129 expected prevalence of C. trachomatis in a population that receives screening at a rate 130 c. To this end, we first assume a prevalence p 0 in absence of screening and denote the parameters. To express the uncertainties of previously used estimates, we use the upper and lower bounds of disease-specific parameters that have been used in various models of 147 C. trachomatis transmission dynamics (Kretzschmar et al., 1996; Brunham et al., 2005; 148 Turner et al., 2006a; Low et al., 2007; Regan et al., 2008; Gray et al., 2009; Sharomi 149 and Gumel, 2009). As baseline parameters, we use the mean value of the respective 150 ranges (Table 1) . Since the upper bound for the duration of temporary immunity (1/µ) 151 is life long, we cannot provide the mean value of the range and therefore set the baseline 152 duration of immunity arbitrarily to 90 days.
153
Analytical results were derived in Mathematica (Wolfram Research, Inc., 2008) 
dS dt = r a I a − αS.
data on 82 women, all of whom are infected with C. trachomatis at the beginning, so 172 we can set I a (0) = 1 and S(0) = 0 and solve for I a (t):
The natural clearance rate and the re-infection rate can now be estimated by fitting Eq. the longer a screening programme is in place, the more pronounced is the reduction in 193 prevalence. The new steady-state prevalence that will be approached in the presence of 194 a screening programme will therefore be further reduced. In this model, screening the population at a rate higher than 0.1 per year would eventually be sufficient to eradicate temporary immunity also results in a less pronounced impact of screening. Increasing 254 the duration of temporary immunity decreases the impact of screening even more ( Fig.   255 5B). Regarding the wide range of immunity that has been used in different models so 256 far (gray area), this effect becomes especially strong in the long-term. Here, screening 257 and treating asymptomatically infected people prevents the development of temporary 258 immunity and renders them susceptible immediately. This somewhat counterbalances 259 the otherwise strong impact of screening.
260
Estimating the duration of the asymptomatic period 261 We have shown that the long-term outcome of a screening programme is most sensi- in asymptomatically infected women, we fit a mathematical model to the data (Fig. 6 ).
271
The estimated re-infection rate is low (0.01 per year; 95% CI: -0. 
). As those studies followed a much smaller number of women than Molano et al.
288
(2005) and did not explicitly take the effect of re-infection into account, our new estimate 289 is likely to be more robust.
290
The simplicity of our model facilitates the understanding of basic properties of the The baseline values of diseasespecific parameters for the SEIRS model are given as the mean values from the range of parameters that have been used in several mathematical and computational models so far (Kretzschmar et al., 1996; Brunham et al., 2005; Turner et al., 2006a; Low et al., 2007; Regan et al., 2008; Gray et al., 2009; Sharomi and Gumel, 2009) . As an exception, we assume 90 days for the baseline duration of temporary immunity (1/µ per day Screening rate with 1/x being the average interval in years at which people receive screening. Note that the fraction of people that get screened at least once within a year is given by 1 − e −x . Figure 1 : SEIRS model illustrating infection with C. trachomatis and subsequent transitions through the different stages of infection. Susceptibles, S, get infected by infected people, I a + I s , at a rate β. They then move through an incubation period (E) at a rate γ to become either asymptomatically infected (I a ) or symptomatically infected (I s ). f denotes the fraction of infections that become asymptomatic. Asymptomatically infected people recover through natural clearance at a rate r a and develop temporary immunity to re-infection (R) for a duration of 1/µ. Symptomatically infected people clear the infection at a rate r s that can be ascribed to treatment seeking due to symptoms. Both asymptomatically and symptomatically infected people get screened and directly treated at a rate c. The low re-infection rate indicates that the data is mainly described by natural clearance and we obtain a mean duration of the asymptomatic period of 433 days (95% CI: 420-447 days). trachomatis within that group. The gray area within each bar corresponds to the total amount of infections within the group. The overall prevalence is given by the dashed line. Population size: 10'000. Varying the duration of the asymptomatic period (1/r a ) together with the duration of temporary immunity (1/µ). The range of parameters that have been previously used is outlined by the white dashed rectangle and the baseline scenario is given by the white dots (Table 1) . The white area indicates extinction of the infection from the population. Figure 9 : Infection rate β and the mean duration of infectiousness as a function of diseasespecific parameters. Changing the fractions of infections becoming asymptomatic (A), the duration of the symptomatic period (B) and the duration of the asymptomatic period (C) within the range that has been previously used (gray area) results in values of β (solid lines) that are between 1.3 and 3.9 per person per year. Taking into account symptomatic and asymptomatic infections, the mean duration of infectiousness (f /r a + (1 − f )/r s , dashed lines) is in the range of 101-300 days.
